Calcimedica - Prospectus Covers Resale of up to 56,020,287 Shares of Common Stock - SEC Filing

Calcimedica Announces Annual Shareholder Meeting

Calcimedica Files Initial Beneficial Ownership Statement for Alafi Capital Co LLC

Calcimedica Files Form 3 Initial Beneficial Ownership Statement for Director Evgeny Zaytsev

CalciMedica Announces Board Expansion and Leadership Transition

Calcimedica Names Evgeny Zaytsev to Board as Director Expands to Eight Members

Calcimedica Director Fred A. Middleton Acquires 248,972 Common Shares Worth $200,000

CalciMedica Advances Auxora After Favorable FDA Safety Review

Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and CalciMedica (CALC)

CalciMedica Says Auxora Phase 2 Trial May Continue Dosing After FDA Review

CalciMedica Amends Loan, Issues New Equity Warrants

CalciMedica announces $49M private placement

Calcimedica - Proceeds to Support Phase 1B Auxora Study in Pah and Cm5480 Ind Clearance, Data Expected Mid-2027

Calcimedica - Anticipates Cash Runway into Second Half of 2027 with Upfront Proceeds

Calcimedica Announces Private Placement Financing for up to Approximately $49 Million to Advance Pulmonary Hypertension Program

Calcimedica - FDA Review Allows Calcimedica to Continue Dosing Auxora in Kourage Trial

Calcimedica Announces Clinical Development of Auxora May Proceed Following FDA Review of Kourage Trial Interim Safety Data

Calcimedica - Expects FDA Feedback on Auxora Pancreatitis Program in Q3 2026

Calcimedica - Lender Extends Interest-only Period to Sept 30, 2027 and Maturity to Sept 1, 2029 - SEC Filing

Calcimedica - Enters First Amendment to Loan and Security Agreement on June 23, 2026 - SEC Filing